Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Show more
Location: 500 North Beacon Street, Suite 230, Watertown, MA, 02472, United States | Website: https://www.kymeratx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
3.121B
52 Wk Range
$19.45 - $53.27
Previous Close
$45.21
Open
$44.57
Volume
596,847
Day Range
$43.87 - $45.15
Enterprise Value
2.465B
Cash
463.2M
Avg Qtr Burn
-58.52M
Insider Ownership
2.50%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KT-621 Details Asthma | Phase 2b Initiation | |
KT-621 Details Atopic dermatitis | Phase 1 Data readout | |
KT-294 Details Inflammatory disease, Autoimmune disease | Phase 1 Data readout | |
KT-621 Details Inflammatory disease, Allergy | Phase 1 Update | |
KT-485 (IRAK4 degrader) Details Immunology | Phase 1 Initiation | |
KT-579 Details Inflammatory disorders | Phase 1 Initiation | |
KT-474 Details Hidradenitis suppurativa, Rheumatoid arthritis, Atopic dermatitis | Failed Discontinued | |
KT-295 Details Inflammatory bowel disease, Psoriasis | Failed Discontinued | |
KT-333 Details Solid tumor/s, Cancer | Failed Discontinued | |
KT-253 Details Solid tumor/s, Cancer, Acute myeloid leukemia, Lymphoma | Failed Discontinued | |
KT-413 Details Solid tumor/s, Cancer | Failed Discontinued |